This technology uses lung-targeting lipid nanoparticles to deliver IL-10 mRNA directly to the lungs, reducing inflammation and injury in conditions like acute lung injury and ARDS, while minimizing side effects and improving treatment effectiveness.
Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe, life-threatening conditions characterized by widespread inflammation and damage to the lung tissue, leading to respiratory failure and high mortality rates. Despite decades of research, there are currently no FDA-approved pharmacologic therapies specifically targeting the underlying inflammation and tissue injury in ALI and ARDS. The clinical management of these conditions is largely supportive, relying on mechanical ventilation and general critical care measures, which do not address the root causes of lung dysfunction. The urgent need for effective, targeted therapies is underscored by the high morbidity and mortality associated with these syndromes, as well as the lack of options for directly modulating the inflammatory processes that drive disease progression. Current approaches to delivering anti-inflammatory therapies, such as systemic administration of interleukin-10 (IL-10) protein, are hampered by several significant limitations. Systemic IL-10 therapy suffers from poor pharmacokinetics, including rapid clearance and a short half-life, which necessitate frequent dosing and limit sustained therapeutic effects. Additionally, the lack of lung specificity means that high systemic doses are required to achieve therapeutic concentrations in lung tissue, increasing the risk of off-target toxicity and adverse effects. Conventional lipid nanoparticle (LNP) systems, such as those used in mRNA vaccine delivery, do not preferentially accumulate in the lungs, further reducing the efficiency of lung-targeted therapy. These challenges highlight the need for novel delivery systems capable of selectively targeting lung tissue, sustaining therapeutic protein expression in situ, and minimizing systemic exposure to improve both efficacy and safety in the treatment of ALI and ARDS.
Technology Overview: This technology is a lung-targeting lipid nanoparticle (sLNP) system engineered for the precise delivery of anti-inflammatory agents to lung tissue, to treat acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The sLNPs are constructed from sulfonium lipids, which confer unique properties enabling selective accumulation in the lungs and robust, uniform expression of protein across all lung lobes. This approach sustains therapeutic protein expression directly within lung tissue while minimizing systemic exposure, thereby reducing potential side effects. What differentiates this technology is its lung specificity and the use of sulfonium lipid chemistry, which sets it apart from conventional amine-based lipid nanoparticles commonly used. Traditional LNPs lack organ selectivity, often requiring higher systemic doses that can increase toxicity and limit therapeutic efficacy, especially for lung diseases. In contrast, the sLNP platform enables targeted delivery and sustained local expression of therapeutics, overcoming the pharmacokinetic limitations and short half-life associated with systemic therapies. This targeted approach not only enhances therapeutic outcomes for ALI and ARDS but also opens avenues for treating other pulmonary inflammatory conditions and advancing pulmonary drug delivery. The technology’s novel combination of materials and delivery strategy positions it as a promising solution for unmet clinical needs in respiratory medicine.
https://suny.technologypublisher.com/files/sites/adobestock_874720379.jpeg
Advantages: • Selective delivery of IL-10 mRNA specifically to lung tissue, enhancing treatment precision for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). • Robust and uniform expression of therapeutic IL-10 protein across all lung lobes, ensuring effective local anti-inflammatory and tissue-protective effects. • Sustained in situ IL-10 protein expression, overcoming limitations of short half-life and poor pharmacokinetics associated with systemic IL-10 therapy. • Reduced systemic exposure and associated side effects, improving safety compared to non-targeted delivery methods. • Use of sulfonium lipid nanoparticles (sLNPs) enables selective lung accumulation, differentiating it from conventional amine-based lipid nanoparticles. • Potential applicability to a broad range of pulmonary inflammatory diseases beyond ALI and ARDS. • Significant reduction of lung injury demonstrated in preclinical models, indicating strong therapeutic potential.
Applications: • ALI/ARDS therapeutic development • Pulmonary anti-inflammatory drug delivery • Lung-targeted mRNA therapeutics
Intellectual Property Summary: Patent application 63/922,741 filed 11/21/2025
Stage of Development: 4 TRL 4. The technology is at an early preclinical stage of development, demonstrating proof‑of‑concept and feasibility of lung‑targeted delivery using sulfonium‑based LNPs in laboratory and initial in vivo models.
Licensing Status: This technology is available for licensing.